Source comparison
Ipamorelin Side Effects Long Term Research: Safety vs Efficacy Comparison
Serious Adverse Events (Grade ≥3) <3% (Mayo Clinic, UVA trials) 12–18% (peripheral edema, carpal tunnel, joint pain) 8–14% (cortisol-mediated insulin resistance) Ipamorelin demonstrates the lowest SAE rate across all GH-modulating therapies studied beyond one
This comparison does not assign a generated winner or score.
- Serious Adverse Events (Grade ≥3)
- <3% (Mayo Clinic, UVA trials)
- 12–18% (peripheral edema, carpal tunnel, joint pain)
- 8–14% (cortisol-mediated insulin resistance)
- Ipamorelin demonstrates the lowest SAE rate across all GH-modulating therapies studied beyond one year
- HPGH Axis Suppression
- 0%. Feedback loops preserved
- 60–80% suppression by month 12
- Minimal (ghrelin pathway intact)
- Only exogenous GH produces clinically significant axis shutdown
- Glucose Homeostasis (HbA1c change)
- −0.1 to +0.2% (neutral to improved)
- +0.4 to +0.9% (insulin resistance common)
- +0.3 to +0.7% (cortisol-driven IR)
- Ipamorelin is the only intervention that maintains or improves glycemic control
- Cardiovascular Markers (LV mass, arterial stiffness)
- No clinically significant change
- LV hypertrophy in 15–22% by month 18
- Minimal change
- Supraphysiologic GH drives cardiac remodeling; ipamorelin stays within physiologic range
- Dependency/Withdrawal Effects
- None. Endogenous GH recovers within 2 weeks
- Prolonged suppression (6–12 months recovery)
- Minimal
- Receptor-mediated therapies (ipamorelin, GHRP-6) preserve endogenous function